go to contents go to 1depth menu
Heal the world,
Better Life

CJ HealthCare

We, CJ HealthCare, strive to create a healthy world.

Our vision
Heal the World, Better Life
Our Mission
We shall endeavor to build a disease-free world by developing innovative treatments and differentiated healthcare contents.
About CEO Kang Seok-hee
CJ HEALTHCARE CEO Greetings by SeokHee KANG CEO Greeting
To achieve our business vision of 'Heal the World, Better Life,' we will develop global innovative new drugs with a spirit of creativity and innovation and repay the national citizens and customers for their support.

About Us

CJ Healthcare was established in 1984 as CJ CheilJedang Pharmaceutical Business Division, based on 30 years of pharmaceutical business know-how.


In 1986, we developed hepatitis prevention vaccine 'Hepaccin-B' with pure domestic technology. We were recognized for our technological capability by mass-producing ‘interferon,’ which was a state-of-the-art basic medicine at that time and 7-ACA, the raw material that requires fine chemical technology.

Bag-type IV Solutions

By producing safe-flex bags for the first time in Korea in 1992, we have brought innovation to the healthcare environment where glass containers used to cause inconvenience in use.


CONDITION, the most popular anti-hangover drink in Korea, has been the indisputable No. 1 brand since 1992 when it first opened the anti-hangover drink market in Korea.


In 1995, CJ HealthCare was  the first domestic pharmaceutical company to achieve $ 100 million in exports and led the growth of the industry. With the continuous R&D investment, we launched a renal anemia treatment EPO formulation (product name: EPOKINE) in 1998 and this was the world's third and for the first time in Korea, leading the localization of pharmaceuticals.


In 2006, we successfully strengthened our product portfolio by merge and acquisition of Han-il Pharmaceutical Corp. In 2010, we completed the construction of the Osong plant, the world-class pharmaceutical production facility, giving a leap to become a global pharmaceutical company.
On April 1st, 2014, CJ Healthcare announced its new start and is in its preparation for the future through active R&D investment and Open Innovation.
Open Innovation Forum photo
CJ Healthcare Vision In October 2015, CJ Healthcare achieved a tremendous success in out licensing the technology of K-CAB Tab. (ingredient name: Tegoprazan), a new drug for Gastroesophageal acid reflux, to Luoxin, one of China's leading pharmaceutical companies with focus in digestive medicine. K-CAB Tab. is expected to be launched in 2019 in Korea and is regarded as a highly evaluated new drug both domestically and globally. CJ Healthcare enhances the speed and success of new drug development through open innovation with domestic and overseas biotech companies and universities, and concentrates its own ability on securing future innovative technologies. In 2014, we made a business alliance to develop protein therapeutics with Pangen. In May 2016, we signed a joint development contract with Y-BioLogics, a new antibody developing company, for a dual target antibody, and we have been co-developing immune anticancer drugs, etc. In addition, we are leading the development of the domestic pharmaceutical industry by introducing the advanced technology through the 'R&D Open Innovation Forum' with domestic, as well as biotech companies in the US, Japan and Europe. CJ Healthcare concentrates on R&D to become a global pharmaceutical company with world-class innovative drugs by accelerating the development of new biologics as well as new chemical entities. In 2020, we will accelerate global expansion beyond sales of 1 trillion KRW, and lead the way in CSV (creating shared value) management, and implement the vision of 'Heal the world, Better Life'.